B-cell small lymphocytic lymphoma refractory

3 trials 1 recruiting MedDRA PT
3 Registered trials
1 Recruiting
3 Unique sponsors
1 Unique IMPs
3 Commercial trials
Drug classes (ATC)
— ATC code not specified 3
Mechanism of action (INN-stem analysis)
Unknown / small molecule 1 substance
Phase II: 1 Phase I: 2

Filter these 3 trials by country, sponsor, date range and more.

Open in Search → Gap analysis →
Show: 3 trials

Phase II

1 trial
  • Nurix Therapeutics Inc. Commercial
    NX-5948
    2025-521088-10-00 4 countries 2025 n=41 Orphan
    Recruiting

Phase I

2 trials
  • Biomea Fusion Inc. Commercial
    IMP not specified
    2024-515744-23-00 2 countries 2023 n=30
    Ended
  • Ubix Therapeutics Inc. Commercial
    IMP not specified
    2023-510484-35-00 1 country n=42
    Pending
Sponsor activity
SponsorTypeTrialsPhasesRecruiting
Biomea Fusion Inc. Commercial 1 Phase I 0
Ubix Therapeutics Inc. Commercial 1 Phase I 0
Nurix Therapeutics Inc. Commercial 1 Phase II 1
New trials by year
2023
1
2025
1
← All indication landscapes